首页> 外文期刊>European Journal of Pharmacology: An International Journal >Electrophysiological effects of azimilide in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium.
【24h】

Electrophysiological effects of azimilide in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium.

机译:阿齐米利在豚鼠心室心肌模拟缺血和再灌注体外模型中的电生理作用。

获取原文
获取原文并翻译 | 示例
       

摘要

There are few investigations on azimilide effects during ischemia/reperfusion. We have therefore investigated low concentrations of azimilide (0.1 and 0.5 micromol/l) versus Controls on action potential parameters and occurrence of repetitive responses during simulated ischemia and reperfusion. An in vitro model of "border zone" in guinea-pig ventricular myocardium (n=30) was used. Azimilide 0.5 micromol/l lengthened action potential duration in normoxic but not in ischemic-like conditions. Therefore an increased dispersion of action potential duration at 90% of repolarization during simulated ischemia in presence of azimilide was seen. Upon reperfusion, both normal and reperfused myocardium showed azimilide-induced action potential duration increase. There was a neutral effect on the occurrence of arrhythmias during simulated ischemia; however azimilide showed significant (P=0.033) antiarrhythmic properties following reperfusion. To mimic I(Kr) and I(Ks) blocking properties of azimilide we further used dofetilide 10 nmol/l with HMR 1556 1 nmol/l (N=9), which was accompanied by less severe shortening (P<0.05) of action potential duration at 90% of repolarization at 30 min of ischemic-like conditions (-43+/-9%), as compared with azimilide 0.5 micromol/l (-64+/-5%) but similar to what seen with azimilide 0.1 micromol/l (-53+/-5%) and Controls (-52+/-6%). During reperfusion, 2/9 (22%) preparations had sustained activities, which was less than what observed in Controls (5/10, 50%) and with azimilide 0.5 micromol/l (0/10, 0%), although not statistically different (respectively, P=0.35 and P=0.21). Lack versus homogenous class III effects of azimilide in respectively simulated ischemia and reperfusion may explain its different efficacy on arrhythmias, although prevention of reperfusion arrhythmias calls for other than just its I(Kr) and I(Ks) blocking properties.
机译:关于缺血/再灌注期间阿齐米利作用的研究很少。因此,我们在模拟的局部缺血和再灌注过程中研究了低浓度的阿齐米利(0.1和0.5 micromol / l)相对于对照的动作电位参数和重复反应的发生。使用了豚鼠心室心肌(n = 30)的“边界区”的体外模型。在常氧性但非缺血性条件下,叠氮内酯0.5 micromol / l延长了动作电位的持续时间。因此,在存在阿齐米利的模拟缺血中,在复极化的90%时,动作电位持续时间的分散性增加了。再灌注后,正常和再灌注心肌均显示阿齐米利诱导的动作电位持续时间增加。模拟缺血期间心律失常的发生具有中性作用;然而,阿齐米利在再灌注后显示出明显的(P = 0.033)抗心律不齐特性。为了模拟阿齐米利的I(Kr)和I(Ks)阻滞特性,我们进一步使用多非利特10 nmol / l和HMR 1556 1 nmol / l(N = 9),同时伴有作用时间缩短幅度较小(P <0.05)在类似缺血的条件下(30分钟)(-43 +/- 9%),在复极化90%时的潜在持续时间,与阿齐米利0.5微摩尔/升(-64 +/- 5%)相比,但与阿齐米利0.1类似微摩尔/升(-53 +/- 5%)和对照(-52 +/- 6%)。在再灌注期间,2/9(22%)制剂具有持续活性,低于对照组(5/10,50%)和阿齐米利0.5 micromol / l(0/10,0%)观察到的活性,尽管没有统计不同(分别为P = 0.35和P = 0.21)。尽管在预防再灌注性心律不齐方面,除了其I(Kr)和I(Ks)阻断特性外,阿兹密利在模拟的局部缺血和再灌注中缺乏III类同质效应还是可能解释了其对心律不齐的不同疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号